Weitz & Luxenberg is no longer accepting Trasylol cases
FREE information from a Trasylol lawyer: FDA Issues Public Health Advisory for Trasylol.
Trasylol, known generically as aprotinin, was used to control bleeding in hundreds of thousands of heart-bypass patients since the Food and Drug Administration (FDA) approved it in 1993.
Bayer AG, marketer of the drug, was forced to pull it from the market last year, after researchers linked it to serious side effects like kidney failure, heart attacks, and strokes.
Some who have been harmed by the pharmaceutical have begun to seek out our Drug and Medical Device lawyers.
Two studies published in the February 2008 issue of the New England Journal of Medicine support earlier finding that the drug is unsafe.
Research studies have linked Trasylol to an increased risk of:
If you experienced complications after surgery, be in touch with your physician to determine if Trasylol was used during the procedure. Please complete the form below for more information from a Trasylol lawyer. A representative of our firm will contact you as soon as possible.
Trasylol Warning 12.06 FDA Issues Label Revision to Trasylol For Warning on Renal Disfuction
Updated Trasylol Warning on Risk of Renal Disfunction and Dialysis
Trasylol Side Effects Trasylol During Heart Surgery May Cause Serious These Side Effects
Heart Surgery Patients Were at Risk for Side Effects from Trasylol
Learn More Learn more about the FDA Trasylol alert from an experienced lawyer
Health Alert: Learn about the FDA Advisory for Trasylol from a lawyer